Boston Scientific to Acquire Claret Medical

 

July 20, 2018—Boston Scientific Corporation announced it has signed an agreement to acquire Claret Medical, Inc., a privately held company that has developed and commercialized the Sentinel cerebral embolic protection system. Claret Medical is based in Santa Rosa, California, and has approximately 120 employees.

The Sentinel system received CE Mark approval in 2014 and FDA clearance in 2017 and is designed to protect patients against the risk of stroke during transcatheter aortic valve replacement procedures.

According to Boston Scientific, the transaction price includes $220 million in upfront cash and a potential reimbursement-based milestone payment of up to $50 million. The acquisition is projected to close during the third quarter of 2018, subject to customary closing conditions.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.